Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Depressive Disorder, Major: early-phase trial registry
14 of 53 indexed Depressive Disorder, Major trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #265 of 28,707 conditions by registered trial count.
53 US clinical trials · 14 currently recruiting · #265 of 28,707 conditions by registered trial count
Depressive Disorder, Major: 53 US clinical trials tracked, 14 recruiting.
Depressive Disorder, Major is the subject of 53 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 11 of these trials.
Enrollment posture brief
Registry condition depressive-disorder-major
OPEN 14 | RECR 26% | LATE 13 | EARLY 22 | RANK #265 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage IIA Breast Cancer AJCC v8 (26% recruiting · 34 trials)
Depressive Disorder, Major lists 14 open slots (26% of 53 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Depressive Disorder, Major on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Depressive Disorder, Major is recruiting below its size-band peers.
14 of 53 indexed trials (26.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Depressive Disorder, Major research.
Janssen Research & Development accounts for 11 of 53 trials (20.8%). 32 distinct sponsors appear on at least one study for this condition label.
-
Typical Depressive Disorder, Major enrolment sits around 124 participants.
Median target enrolment is 124 among the 53 trials that report a genuine target (sentinel values excluded). 23 of those (43.4%) plan for fewer than 100 participants.
-
Depressive Disorder, Major research is mostly interventional.
45 interventional and 8 observational studies make up this index (84.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
53 total, page 1 of 2
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
NCT07412756
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development
NCT06559306
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development
NCT07227454
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
GrayMatters Health
NCT06982820
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
Janssen Research & Development
NCT06785012
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
Mclean Hospital
NCT05232032
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
Massachusetts General Hospital
NCT06136546
A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)
Janssen Research & Development
NCT07258485
InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
University of Washington
NCT06005194
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
National Institute of Mental Health (NIMH)
NCT06511908
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Yale University
NCT05915013
Biomarkers of Depression and Treatment Response
University of California, San Francisco
NCT04581902
Dosing rTMS for Depression Post-SCI
VA Office of Research and Development
NCT05553353
Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness
VA Office of Research and Development
NCT05491538
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
Janssen Research & Development
NCT05518149
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
Janssen Research & Development
NCT05841030
Psilocybin for Major Depressive Disorder (MDD)
Usona Institute
NCT06308653
Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS
Stanford University
NCT04870255
Individualized Functional Connectivity Targeting in aiTBS for Depression
Brigham and Women's Hospital
NCT05680727
Altering Default Mode Network Activity With Transcranial Focused Ultrasound to Reduce Depressive Symptoms
University of Arizona
NCT06320028
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
Otsuka Pharmaceutical Development & Commercialization
NCT02196506
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
Medibio Limited
NCT05708222
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder
Takeda
NCT01564862
A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder
Sumitomo Pharma America
NCT00368030
A Safety, Efficacy and Tolerability Study of SEP-225289
Sumitomo Pharma America
NCT00584974
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
Eli Lilly and Company
NCT00105989
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
Takeda
NCT01179516
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
Naurex, Inc, an affiliate of Allergan
NCT02932943
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Janssen Research & Development
NCT05550532
Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)
Janssen Research & Development
NCT02489305
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Janssen Research & Development
NCT03227224
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
Allergan
NCT02116361
AGN-241751 in the Treatment of Major Depressive Disorder
Syndeio Biosciences
NCT03586427
Mothers With a History of Depression and Their 10-14 Year Old Daughters
Stanford University
NCT01129752
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Janssen Research & Development
NCT03039192
A Study to Test Different Doses of BI 1569912 in People With Depression
Boehringer Ingelheim
NCT06558344
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
Janssen Research & Development
NCT03559192
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
Seelos Therapeutics
NCT04669665
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
Tonix Pharmaceuticals
NCT05686408
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Tal Medical
NCT02452892
Clinical and Biological Characteristics of Psychotic Depression
Stanford University
NCT00576095
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
University of Pittsburgh
NCT00149643
Insulin Resistance in Patients With Major Depression
Stanford University
NCT01106313
In-person vs. Remote Wellness Support
The University of Texas Health Science Center at San Antonio
NCT04526067
Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1
National Institute on Drug Abuse (NIDA)
NCT00218556
A Study of LY2216684 in Participants With Impaired Hepatic Function
Eli Lilly and Company
NCT01241435
Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression
Yale University
NCT03027362
A Study to Evaluate the Effect of Food on LY2216684
Eli Lilly and Company
NCT01389765
A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
Eli Lilly and Company
NCT01389752
Patient Tolerability Study of GSK163090
GlaxoSmithKline
NCT00559299
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 16 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Depressive Disorder, Major records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Depressive Disorder, Major trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Depressive Disorder, Major page
53 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Depressive Disorder, Major trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Depressive Disorder, Major trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Depressive Disorder, Major condition card totals 53 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.